IRIS
ANGARANO, Gioacchino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.787
AS - Asia 9.502
EU - Europa 8.754
SA - Sud America 2.758
AF - Africa 433
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 12
AN - Antartide 2
Totale 46.264
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.501
SG - Singapore 3.897
IT - Italia 2.638
BR - Brasile 2.219
CN - Cina 2.138
DE - Germania 1.514
HK - Hong Kong 1.505
SE - Svezia 870
UA - Ucraina 832
RU - Federazione Russa 752
FI - Finlandia 654
VN - Vietnam 558
FR - Francia 555
GB - Regno Unito 466
IN - India 317
BD - Bangladesh 227
AR - Argentina 187
CA - Canada 125
IQ - Iraq 125
CI - Costa d'Avorio 120
ID - Indonesia 102
ZA - Sudafrica 97
MX - Messico 89
EC - Ecuador 88
TR - Turchia 80
CO - Colombia 73
PK - Pakistan 73
BE - Belgio 69
SA - Arabia Saudita 65
VE - Venezuela 65
IE - Irlanda 59
JP - Giappone 59
PL - Polonia 55
MA - Marocco 51
ES - Italia 48
UZ - Uzbekistan 47
NL - Olanda 43
PY - Paraguay 43
TN - Tunisia 37
CL - Cile 34
PH - Filippine 34
KE - Kenya 33
AT - Austria 32
JO - Giordania 32
MK - Macedonia 27
IR - Iran 26
EG - Egitto 22
MY - Malesia 22
AE - Emirati Arabi Uniti 20
IL - Israele 20
NP - Nepal 19
AZ - Azerbaigian 18
ET - Etiopia 17
UY - Uruguay 17
PE - Perù 16
KZ - Kazakistan 14
LB - Libano 14
LT - Lituania 14
BG - Bulgaria 13
CR - Costa Rica 13
OM - Oman 13
PS - Palestinian Territory 13
RO - Romania 13
RS - Serbia 13
BO - Bolivia 12
JM - Giamaica 12
CZ - Repubblica Ceca 11
GE - Georgia 11
GR - Grecia 11
HR - Croazia 11
TH - Thailandia 11
AU - Australia 10
DZ - Algeria 10
EU - Europa 10
HN - Honduras 10
AL - Albania 9
BY - Bielorussia 9
NG - Nigeria 9
CH - Svizzera 8
KW - Kuwait 8
NI - Nicaragua 8
BH - Bahrain 7
DO - Repubblica Dominicana 7
HU - Ungheria 6
LY - Libia 6
PT - Portogallo 6
SN - Senegal 6
AO - Angola 5
TT - Trinidad e Tobago 5
XK - ???statistics.table.value.countryCode.XK??? 5
BB - Barbados 4
PA - Panama 4
QA - Qatar 4
SY - Repubblica araba siriana 4
AM - Armenia 3
BW - Botswana 3
KH - Cambogia 3
KR - Corea 3
LV - Lettonia 3
SV - El Salvador 3
Totale 46.209
Salva come PNG Salva come JPEG
Città #
Fairfield 2.714
Ashburn 2.056
Singapore 2.005
Woodbridge 1.991
Jacksonville 1.862
Chandler 1.704
Houston 1.502
Hong Kong 1.486
San Jose 1.184
Seattle 1.122
Milan 1.071
Wilmington 1.005
Cambridge 910
Ann Arbor 840
Nyköping 577
Beijing 491
Dallas 480
Lawrence 465
Roxbury 464
Nanjing 448
Lauterbourg 412
New York 372
Rome 363
Boardman 295
Des Moines 294
Los Angeles 265
Princeton 231
Helsinki 202
São Paulo 186
Ho Chi Minh City 173
Santa Clara 151
Bari 135
Shenyang 128
Buffalo 126
Abidjan 120
Hebei 120
Hanoi 119
Inglewood 119
Columbus 113
Munich 113
San Diego 113
Dearborn 111
Nanchang 110
Brooklyn 99
Figino 96
Council Bluffs 83
London 74
Jiaxing 73
Rio de Janeiro 71
Turin 71
Tianjin 69
Dublin 58
Tokyo 56
Baghdad 53
Brussels 53
Falkenstein 52
Dong Ket 46
Jakarta 46
Moscow 46
Belo Horizonte 45
Curitiba 45
Guangzhou 45
Pune 45
Chicago 44
Brasília 43
Warsaw 43
Naples 41
Frankfurt am Main 39
Changsha 38
Johannesburg 38
Tashkent 38
Orem 37
Paris 36
Atlanta 35
Montreal 33
Denver 31
Chennai 30
Mexico City 30
New Delhi 30
Taranto 30
Hefei 29
Salvador 29
San Francisco 29
Campinas 28
Guayaquil 28
Nairobi 28
Porto Alegre 28
Toronto 28
Amman 27
Dhaka 27
Stockholm 27
Nuremberg 26
Asunción 25
Da Nang 25
Mumbai 25
Caracas 24
Quito 24
Riyadh 24
Washington 24
Jeddah 23
Totale 31.118
Salva come PNG Salva come JPEG
Nome #
Anemia as a risk factor for disease progression in patients admitted for COVID-19: data from a large, multicenter cohort study 417
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 378
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 367
Sphingomonas paucimobilis outbreak in a dialysis room: Case report and literature review of an emerging healthcare associated infection 279
Economic evaluation of HIV treatments: The I.CO.N.A. cohort study 241
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 226
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 216
Access to health services for undocumented immigrants in Apulia. 212
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 208
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 201
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 196
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 192
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 192
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 186
An outbreak of HIV-1 BC recombinants in Southern Italy 183
Access to HAART in HIV-Infected Immigrants: A Retrospective Multicenter Italian Study 179
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 176
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 176
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. 171
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients 170
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 169
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 166
" INFEZIONI DA CLAMYDIA PNEUMONIAE IN PAZIENTI CON A.I.D.S. " 165
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 164
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 164
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 163
The elderly and direct antiviral agents: Constraint or challenge? 162
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 161
Cryptosporidiosis in the acquired immunodeficiency syndrome: a case report 160
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. 160
A cyanobacterium-like body found in the stools of an HIV+ patient with diarrhoea 159
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study 159
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 159
Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. 158
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 156
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 155
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016 154
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 153
Co-receptor switch during HAART is independent of virological success 151
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 151
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 150
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 149
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 149
Splenic abscesses as a first manifestation of Crohn's disease: A case report 148
Knowledge, attitudes, and practices about HIV and other sexually transmitted infections among High School students in Southern Italy: A cross-sectional survey 147
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 147
Alterazioni oftalmoscopiche e fluorangiografiche in pazienti affetti da AIDS 146
Access to Health Services for Undocumented Immigrants in Apulia 146
Incidence of tuberculosis among HIV-Infected patients receiving highly active antiretroviral therapy in Europe and North America 146
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. 145
Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents 145
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 144
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 143
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 142
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 142
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 139
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 139
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 137
Are the proposed env mutations actually associated with resistance to maraviroc? 137
Evolution of antiretroviral prescription and response over a period of 8 years: An Italian multicentre observational prospective cohort study 136
Persistence of e antigen as prognostic marker in acute hepatitis B 135
Intrathecal immune response in human immunodeficiency virus infection 135
Epidemiological multicentric Italian society of infectious and tropical diseases study on prevalence of tropical diseases in hospitalized immigrants in Italy during 2002 135
Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin 135
Gaining back what is lost: recovering the sense of smell in mild to moderate patients after COVID-19 135
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 134
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients 134
Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection 133
Long-term efficacy and safety of switching from lamivudine + adefovir to tenofovir disoproxil fumarate in virologically suppressed patients 133
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 133
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 132
Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens 132
Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study 132
L'anticorpo antinucleare (anti-HBc) e patologia acuta e cronica del fegato da virus B dell'epatite 131
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 131
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir 131
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 131
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections 130
Parkinsonism in a patient with AIDS and cerebral opportunistic granulomatous lesions 130
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 129
Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors 129
Adherence of hiv patients switching to emtricitabina+tenofovir disoproxil+rilpivirin. Real world evidence from italian administrative databases 129
Pulmonary Artery Filling Defects in Covid-19 Patients Revealed Using CT Pulmonary Angiography: A Predictable Complication? 129
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years 128
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 128
Immunological markers in HIV-infected pregnant and non-pregnant women 128
Frequent cervicovaginal shedding of HIV-1 in asymptomatic, non-severely immunodeficient women 127
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 127
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 127
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study 126
Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy 126
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 126
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 126
Risk of AIDS in HIV seroconverters: a comparison between intravenous drug users and homosexual males 125
HCV and diabetes: Towards a 'sustained' glycaemic improvement after treatment with DAAs? 125
Hepatitis B virus markers, alpha-fetoprotein and survival in fulminant viral hepatitis 124
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 123
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 122
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort 122
Cell cultures from small amounts of heparinized whole blood enhance HIV-1 isolation rate 121
Totale 15.801
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.299
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.299
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.793 111 370 36 232 137 183 103 196 183 170 452 620
2022/20234.439 797 317 185 448 630 517 39 504 775 34 101 92
2023/20241.501 143 343 83 75 95 394 39 39 28 41 30 191
2024/20256.263 89 117 688 215 110 543 333 556 278 323 934 2.077
2025/202614.073 1.850 726 1.097 1.551 1.311 747 1.541 400 1.240 1.211 449 1.950
2026/2027426 426 0 0 0 0 0 0 0 0 0 0 0
Totale 46.927